Activated Charcoal Ambergris Ammonium Chloride Arn

證據等級: L5

預測適應症: 0 個

Multi-Component Herbal/Homeopathic Complex: Repurposing Evaluation Not Applicable

One-Sentence Summary

This submission contains a complex mixture of eight components — including Activated Charcoal, Atropa Belladonna, Arnica Montana, and Claviceps Purpurea — whose profile resembles a homeopathic combination product. The TxGNN model returned no predicted indications for this compound, and the drug holds no US market authorizations. Without a defined single active ingredient, DrugBank mapping, or TxGNN output, a standard repurposing evaluation cannot proceed.

Quick Overview

Item	Content
Original Indication	Unknown — no approved indication on record
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction only; in this case, no output at all
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This submission is not a single molecular entity but a mixture of eight pharmacologically distinct substances:

Component	Known Pharmacological Class
Activated Charcoal	Non-specific adsorbent
Ambergris	Historical fragrance/fixative; no defined pharmacology
Ammonium Chloride	Expectorant / urinary acidifier
Arnica Montana	Topical anti-inflammatory (homeopathic)
Atropa Belladonna	Anticholinergic (source of atropine/scopolamine)
Baptisia Tinctoria Root	Immune stimulant (homeopathic)
Claviceps Purpurea Sclerotium	Ergot alkaloid source (homeopathic dilution)
Filipendula Ulmaria Root	Anti-inflammatory (contains natural salicylates)

The TxGNN knowledge graph operates on single-drug entities matched to DrugBank IDs. This combination product could not be assigned a DrugBank ID, which means the model had no node to traverse — producing an empty prediction set rather than a meaningful score.

The combination profile is consistent with a classical homeopathic compound formula, where each ingredient is present at high dilution and the claimed therapeutic mechanism differs fundamentally from conventional pharmacology. This category of product falls outside the scope of TxGNN-based repurposing analysis.

US Market Information

No US market authorizations found. This product has zero NDAs on record.

Safety Considerations

Please refer to the package insert for safety information.

Note for reviewers: Atropa Belladonna contains atropine and scopolamine, which carry anticholinergic risks even at low doses. Claviceps Purpurea (ergot) is a source of vasoconstrictive alkaloids. If any future formulation development moves beyond homeopathic dilutions, a dedicated safety assessment for these two components is strongly recommended.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model produced no output because this multi-component mixture cannot be mapped to a single DrugBank entity, which is a prerequisite for knowledge-graph traversal. There is no original indication, no US market presence, and no evidence base to evaluate.

To proceed, the following is needed:

Reformulate the query: If the intent is to evaluate a specific component (e.g., Atropa Belladonna / atropine, or Filipendula Ulmaria), resubmit as a single-ingredient query with the appropriate DrugBank ID.
Clarify product identity: Confirm whether this is a licensed homeopathic product, an investigational botanical combination, or a data entry artifact.
Obtain regulatory classification: Determine whether the product would be regulated as a drug, dietary supplement, or homeopathic remedy under US FDA rules — each pathway has different evidence requirements.
Manual literature review: If the combination is of genuine research interest, a manual PubMed search by individual component is feasible, but TxGNN-driven repurposing is not applicable in the current form.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.